Evidence map›Paper›PMID 31645346›Full record

ArticleCold Spring Harbor molecular case studies2019

Novel

Mohammed Hassan, Erin Butler, Raphael Wilson, Angshumoy Roy, Yanbin Zheng, Priscilla Liem, Dinesh Rakheja, Dean Pavlick, Lauren L Young, Mark Rosenzweig and 6 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Molecular Characterization of a ComplexJCO precision oncology · 2026
    Article
  3. Article
  4. Concurrent PTEN and PDGFRB Alterations Characterize Storiform Collagenoma.The American journal of surgical pathology · 2024
    Article
  5. Article
  6. High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Mohammed HassanDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Erin ButlerDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Raphael WilsonDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Angshumoy RoyBaylor College of Medicine, Houston, Texas 77030, USA.
Yanbin ZhengDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Priscilla LiemDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Dinesh RakhejaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Dean PavlickFoundation Medicine, Inc, Cambridge, Massachusetts 02141, USA.
Lauren L YoungFoundation Medicine, Inc, Cambridge, Massachusetts 02141, USA.
Mark RosenzweigFoundation Medicine, Inc, Cambridge, Massachusetts 02141, USA.
Rachel ErlichFoundation Medicine, Inc, Cambridge, Massachusetts 02141, USA.
Siraj M AliFoundation Medicine, Inc, Cambridge, Massachusetts 02141, USA.
Patrick J LeaveyDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
D Williams ParsonsBaylor College of Medicine, Houston, Texas 77030, USA.
Stephen X SkapekDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Theodore W LaetschDivision of Hematology/Oncology, Departments of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
The University of Texas Southwestern Medical Center · USEditas Medicine (United States) · USCenter for Cancer and Blood Disorders · USBaylor College of Medicine · USBeam Therapeutics (United States) · US

Funding

ANTECEDANTS SEQUELAE OF CHILDHOOD ONSET DISEASEK12HD068369 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2011 to 2020
$3.0M
NICHD NIH HHS K12 HD068369
6 · The paper itself

Abstract

Infantile myofibromatosis (IM) is an aggressive neoplasm composed of myofibroblast-like cells in children. Although typically localized, it can also present as multifocal disease, which represents a challenge for effective treatment. IM has previously been linked to activating somatic and germline point mutations in the PDGFRβ tyrosine kinase encoded by the

Indexed as

AnimalsCell LineExtracellular Signal-Regulated MAP KinasesFemaleFibroblastsGerm-Line MutationHumansImatinib MesylateInfant, NewbornMiceMyofibromatosisProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaExtracellular Signal-Regulated MAP KinasesImatinib MesylatePDGFRB protein, humanProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaneoplasm of the skin

Identifiers

PMID31645346
PMCPMC6824247
OpenAlexW2982149833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.